Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Scoring systems in mantle cell lymphoma: A critical point of view

Scoring systems in mantle cell lymphoma: A critical point of view A proposal for a scoring system in the diagnosis of chronic lymphoproliferative diseases other than CLL has been recently published in Cytometry Part B. The authors apply this score for deciding whether or not FISH evaluation for the detection of IGH/CCND1 rearrangements must be performed to exclude Mantle Cell Lymphoma (MCL). In their validation series, no MCL scored <3. We have applied their system to our cases of MCL and also to a small series of Marginal Zone lymphomas. In our hands, the scoring system as has been published does not discriminate adequately between both entities. We propose using the negativity of a marker, CD11c, instead of the platelet count to improve the results. However, we believe that given the clinical and prognostic implications of the diagnosis of MCL, scoring systems should be greatly ameliorated prior to their generalized use. © 2011 International Clinical Cytometry Society http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cytometry Part A Wiley

Scoring systems in mantle cell lymphoma: A critical point of view

Download PDF
3 pages

Loading next page...
 
/lp/wiley/scoring-systems-in-mantle-cell-lymphoma-a-critical-point-of-view-2t9CNjncr8

References (12)

Publisher
Wiley
Copyright
"Copyright © 2012 Wiley Subscription Services, Inc., A Wiley Company"
ISSN
1552-4922
eISSN
1552-4930
DOI
10.1002/cyto.b.20620
pmid
21915995
Publisher site
See Article on Publisher Site

Abstract

A proposal for a scoring system in the diagnosis of chronic lymphoproliferative diseases other than CLL has been recently published in Cytometry Part B. The authors apply this score for deciding whether or not FISH evaluation for the detection of IGH/CCND1 rearrangements must be performed to exclude Mantle Cell Lymphoma (MCL). In their validation series, no MCL scored <3. We have applied their system to our cases of MCL and also to a small series of Marginal Zone lymphomas. In our hands, the scoring system as has been published does not discriminate adequately between both entities. We propose using the negativity of a marker, CD11c, instead of the platelet count to improve the results. However, we believe that given the clinical and prognostic implications of the diagnosis of MCL, scoring systems should be greatly ameliorated prior to their generalized use. © 2011 International Clinical Cytometry Society

Journal

Cytometry Part A – Wiley

Published: Mar 1, 2012

Keywords: ;

There are no references for this article.